
Dr. Reddy's (DRREDDY) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
85.5B
Gross Profit
48.6B
56.91%
Operating Income
16.8B
19.71%
Net Income
14.1B
16.50%
EPS (Diluted)
₹17.02
Balance Sheet Metrics
Total Assets
493.0B
Total Liabilities
155.8B
Shareholders Equity
337.2B
Debt to Equity
0.46
Cash Flow Metrics
Operating Cash Flow
27.8B
Free Cash Flow
10.8B
Revenue & Profitability Trend
Dr. Reddy's Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 325.5B | 279.2B | 245.9B | 214.4B | 189.7B |
Cost of Goods Sold | 135.1B | 115.6B | 106.5B | 100.6B | 86.6B |
Gross Profit | 190.4B | 163.6B | 139.3B | 113.8B | 103.1B |
Gross Margin % | 58.5% | 58.6% | 56.7% | 53.1% | 54.3% |
Operating Expenses | |||||
Research & Development | 27.4B | 22.9B | 19.4B | 17.5B | 16.5B |
Selling, General & Administrative | 93.9B | 77.2B | 68.0B | 62.1B | 54.6B |
Other Operating Expenses | -2.8B | -1.8B | -7.1B | -1.6B | -1.0B |
Total Operating Expenses | 118.4B | 98.3B | 80.3B | 77.9B | 70.2B |
Operating Income | 72.0B | 65.3B | 59.1B | 35.9B | 32.9B |
Operating Margin % | 22.1% | 23.4% | 24.0% | 16.8% | 17.3% |
Non-Operating Items | |||||
Interest Income | 2.7B | 2.3B | 1.2B | 965.0M | 826.0M |
Interest Expense | 2.8B | 1.7B | 1.4B | 958.0M | 970.0M |
Other Non-Operating Income | 4.9B | 6.0B | 1.6B | -3.6B | -6.4B |
Pre-tax Income | 76.8B | 71.9B | 60.4B | 32.3B | 26.4B |
Income Tax | 19.5B | 16.2B | 15.3B | 8.7B | 9.2B |
Effective Tax Rate % | 25.4% | 22.5% | 25.3% | 27.0% | 34.7% |
Net Income | 57.2B | 55.7B | 45.1B | 23.6B | 17.2B |
Net Margin % | 17.6% | 19.9% | 18.3% | 11.0% | 9.1% |
Key Metrics | |||||
EBITDA | 92.0B | 82.6B | 73.2B | 49.4B | 47.0B |
EPS (Basic) | ₹67.88 | ₹66.93 | ₹54.29 | ₹28.42 | ₹20.79 |
EPS (Diluted) | ₹67.78 | ₹66.80 | ₹54.17 | ₹28.34 | ₹20.73 |
Basic Shares Outstanding | 832950406 | 831968515 | 830174450 | 829391892 | 829221700 |
Diluted Shares Outstanding | 832950406 | 831968515 | 830174450 | 829391892 | 829221700 |
Income Statement Trend
Dr. Reddy's Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 14.7B | 7.1B | 5.8B | 14.9B | 14.8B |
Short-term Investments | 43.3B | 74.4B | 56.0B | 29.5B | 19.7B |
Accounts Receivable | 90.4B | 80.3B | 72.5B | 66.8B | 49.6B |
Inventory | 71.1B | 63.6B | 48.7B | 50.9B | 45.4B |
Other Current Assets | 4.0B | 2.8B | 5.2B | 3.3B | 4.1B |
Total Current Assets | 250.1B | 248.0B | 204.3B | 181.9B | 148.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 3.0M | 3.0M | 0 | 0 |
Goodwill | 120.4B | 45.5B | 39.3B | 36.1B | 44.8B |
Intangible Assets | 96.8B | 37.0B | 30.8B | 27.2B | 35.6B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 20.6B | 15.4B | 10.0B | 8.5B | 10.9B |
Total Non-Current Assets | 242.9B | 139.5B | 117.6B | 111.0B | 117.2B |
Total Assets | 493.0B | 387.5B | 321.9B | 292.8B | 265.5B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 20.1B | 21.5B | 17.9B | 16.0B | 12.7B |
Short-term Debt | 38.9B | 14.0B | 12.2B | 28.1B | 24.0B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 7.4B | 6.0B | 3.7B | 2.5B | 2.4B |
Total Current Liabilities | 130.4B | 96.0B | 85.8B | 94.0B | 83.4B |
Non-Current Liabilities | |||||
Long-term Debt | 7.9B | 6.0B | 1.3B | 5.7B | 6.3B |
Deferred Tax Liabilities | 14.1B | 909.0M | 833.0M | 60.0M | 338.0M |
Other Non-Current Liabilities | 2.1B | 2.8B | 1.3B | 825.0M | 812.0M |
Total Non-Current Liabilities | 25.4B | 10.9B | 5.0B | 8.3B | 9.0B |
Total Liabilities | 155.8B | 107.0B | 90.9B | 102.3B | 92.4B |
Equity | |||||
Common Stock | 834.0M | 834.0M | 833.0M | 832.0M | 832.0M |
Retained Earnings | 315.8B | 265.3B | 215.6B | 175.7B | 156.0B |
Treasury Stock | 2.3B | 991.0M | 1.3B | 1.6B | 2.0B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 337.2B | 280.6B | 231.0B | 190.5B | 173.1B |
Key Metrics | |||||
Total Debt | 46.8B | 20.0B | 13.5B | 33.8B | 30.3B |
Working Capital | 119.7B | 152.0B | 118.4B | 87.8B | 64.9B |
Balance Sheet Composition
Dr. Reddy's Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 57.2B | 55.7B | 45.1B | 23.6B | 17.2B |
Depreciation & Amortization | 17.1B | 14.8B | 12.6B | 11.8B | 12.8B |
Stock-Based Compensation | 424.0M | 407.0M | 397.0M | 592.0M | 584.0M |
Working Capital Changes | -30.3B | -23.6B | -7.9B | -22.9B | -13.6B |
Operating Cash Flow | 64.1B | 62.9B | 65.8B | 21.8B | 26.4B |
Investing Activities | |||||
Capital Expenditures | -27.0B | -15.3B | -11.2B | -14.3B | 85.0M |
Acquisitions | -53.4B | -12.0M | 0 | -326.0M | -15.5B |
Investment Purchases | -254.5B | -145.5B | -136.2B | -89.0B | -75.4B |
Investment Sales | 279.6B | 129.8B | 112.8B | 77.8B | 79.5B |
Investing Cash Flow | -55.3B | -31.1B | -34.6B | -25.8B | -11.3B |
Financing Activities | |||||
Share Repurchases | -1.4B | - | - | 0 | -1.2B |
Dividends Paid | -6.7B | -6.6B | -5.0B | -4.1B | -4.1B |
Debt Issuance | 0 | 3.8B | 0 | 0 | 3.8B |
Debt Repayment | -1.3B | -4.9B | -1.0B | -785.0M | -4.5B |
Financing Cash Flow | 22.4B | -1.5B | -25.0B | -1.1B | 1.0B |
Free Cash Flow | 12.0B | 18.0B | 40.0B | 9.1B | 23.1B |
Net Change in Cash | 31.2B | 30.4B | 6.2B | -5.1B | 16.1B |
Cash Flow Trend
Dr. Reddy's Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
17.79
Forward P/E
3.53
Price to Book
2.88
Price to Sales
3.02
PEG Ratio
3.53
Profitability Ratios
Profit Margin
16.99%
Operating Margin
20.50%
Return on Equity
17.71%
Return on Assets
9.71%
Financial Health
Current Ratio
1.89
Debt to Equity
13.75
Beta
0.31
Per Share Data
EPS (TTM)
₹68.08
Book Value per Share
₹420.56
Revenue per Share
₹401.36
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
drreddy | 1.0T | 17.79 | 2.88 | 17.71% | 16.99% | 13.75 |
Sun Pharmaceutical | 3.8T | 36.63 | 5.27 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 68.03 | 10.49 | 14.64% | 23.89% | 0.03 |
Torrent | 1.2T | 60.57 | 15.93 | 25.18% | 16.92% | 42.81 |
Cipla | 1.2T | 22.27 | 3.85 | 16.85% | 19.62% | 1.40 |
Mankind Pharma | 1.0T | 53.19 | 7.10 | 13.67% | 14.66% | 58.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.